New data for management of hepatocellular carcinoma
Gastrointestinal cancers

New data for management of hepatocellular carcinoma

The COSMIC-312 trial met its primary endpoint of progression-free survival, but interim overall survival results need further exploration 

Read more
Encouraging results with sintilimab combination therapy in EGFR-mutated non-squamous NSCLC
Lung and other thoracic tumours

Encouraging results with sintilimab combination therapy in EGFR-mutated non-squamous NSCLC

In the first interim analysis of the ORIENT-31 trial, progression-free survival was slightly improved in patients who progressed after EGFR TKI, but mature results are needed to confirm whether combination therapy represents a new therapeutic option in this setting

Read more

Don't miss

  • Pan-Asian adapted ESMO CPG lectures
    21 November 2021, 14:00-17:30, Channel 1
  • ESMO Asia Policy Session
    21 November 2021, 14:00-15:00, Channel 2
  • ESMO Webinar on Gastric Cancer 
    23 November 2021, 19:30-20:20 (SGT), Channel 1

PAN-ASIAN ADAPTED GUIDELINES

HIGHLIGHTS OF THE YEAR

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings